canceldeath
Sign in
Metformin
Registry update — unassessed

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial

Trial registry update: RECRUITING. No results reported in the supplied registry record.

RCTNotable significance
Share on X
Reporter brief

What this changes

The finding has not established an approved change to our evidence assessment.

Source date: Jul 30, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill

What it does not prove

  • No outcomes are reported, so this study proves nothing—it describes a planned investigation only
  • The study protocol does not indicate whether enrollment was completed, participants were followed to endpoint, or any data were collected
  • Even when completed, results from this single trial would require replication to establish whether metformin combinations are effective for weight maintenance after GLP-1 cessation

Extracted from supplied source material; model confidence is not a measured probability of correctness.

Study details

Design
Rct
Sample size
—
Duration
6 months
Population
Patients weaning off GLP-1 medications who have achieved weight loss
Primary outcome
Percentage of weight regain six months after cessation of GLP-1 therapy
Effect size
—
Significance
Not reported
Journal
AgelessRx
Published
Jul 30, 2025

Sources

Primary source

Recorded source passages

Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.

The goal of this randomized, controlled trial is to evaluate the effectiveness of alternative therapies (metformin alone, with rapamycin, and with low-dose naltrexone) in maintaining weight loss in patients weaning off GLP-1 medications.
Researchers will compare the four groups: 1) control, 2) metformin, 3) metformin + rapamycin, and 4) metformin + low-dose naltrexone, to assess changes in the percentage of weight regain, metabolic indicators (e.g., HbA1c, lipid profile), and quality of life PROs, six months after cessation of GLP-1 therapy.
Participants will: Administer the assigned intervention following a dosing and administration protocol provided by the study and medical team.

Source versions

Version 1: Superseded

Version 1: Unassessed

Assessment history

Discussion (0)

One thread per scientific event, no matter how many outlets covered it.

Sign in to join the discussion.

No comments yet

Be the first to weigh in on this evidence.